Eli Lilly and Johnson & Johnson have highlighted risks to Ireland’s pharmaceutical sector as US trade uncertainties grow. Companies warned that EU regulations, supply chain vulnerabilities, and a need for a skilled workforce could impact Ireland’s position as a life sciences hub. Concerns included potential reductions in intellectual property protection for clinical data and the threat of future US tariffs, which could reach 150–250 percent. Officials stressed balancing innovation incentives with affordable medicines, while maintaining predictability for investors and advocating at EU level to protect competitiveness.
Read the full article for a detailed analysis of Ireland’s pharma landscape and trade strategy.
.png)
